News | November 28, 2025
GV20 Therapeutics hits milestone in AI-driven cancer therapy collaboration with Mitsubishi Tanabe Pharma
GV20 received an upfront payment and is eligible for additional milestone payments
GV20 received an upfront payment and is eligible for additional milestone payments
Nitrosamines have prompted evolving global guidelines that demand rigorous industry oversight
Future of manufacturing lies in mobility based manufacturing
The clearance for TELLTALE positions Transmural Systems at the forefront of next-generation electrosurgical solutions for structural heart interventions
The fresh capital will propel Cordance into its first-in-human clinical trial
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
The deal, backed by Gavi and executed by UNICEF, could generate up to US$90 million in savings—enough to provide more than 30 million additional doses
The approval by the US FDA comes after extensive safety testing and manufacturing improvements
RK Pharma will manufacture and supply the finished product, while Zydus will be responsible for the NDA submission and commercialization of the product in the US
Subscribe To Our Newsletter & Stay Updated
